May 3, 2015
Azithromycin appeared to have a high rate of failure among patients infected with Mycoplasma genitalium who demonstrated pre-treatment macrolide resistance, according to recent findings.
Researchers evaluated 155 adult patients treated for M. genitalium infection between July 2012 and June 2013 at the Melbourne Sexual Health Centre in Victoria, Australia. Patients had their infection diagnosed through quantitative PCR and were treated with first-line azithromycin. All were instructed to forgo sexual activity for 14 days and to return for repeat testing between 14 and 28 days after therapy.